Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 4/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 2/20 | 0.49 |
| ▸ | EDNRB | P24530 | 2/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902299 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2GLATSHRGAATRPV4 | |
| SCHEMBL4018384 | 0.85 | TRPV4 (0.66) | SMN1; SMN2GLATSHRGAATRPV4 | |
| SCHEMBL30514814 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL1790129 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL27584635 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL1137871 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL7421633 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL27601631 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2GLATSHRGAAALOX15 | |
| SCHEMBL2701151 | 0.81 | GAA (0.58) | SMN1; SMN2GLATSHRGAATRPV4 | |
| SCHEMBL19692866 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2GLATSHRGAATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729515-A1 | NEW ACYLSULFONAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12428376-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| CN-119409685-B | 4- (1- (Azaacyl-3-butyl) -1H-imidazol-2-yl) anilides PKM2 agonists | 南京医科大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| EP-0906091-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5891909-A | Amidinohydrazones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997036580-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514691-A | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428376-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | SMN1; SMN2 3641/4885GLA 2311/4885TSHR 2017/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | SMN1; SMN2 2143/4885GLA 4443/4885TSHR 4516/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | SMN1; SMN2 3601/4885GLA 3982/4885TSHR 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.